ABSTRACT
Objective:The topic model is a well-known method used in the field of natural language processing (NLP)that defines adocument as constructed of topics that combine specific t erms. This method is used to model topic co-occurrencemathematically. In this study,we extracted topics from featu re vectors of explicit documents called medical package insertsby using cluster analysis. Methods:We counted the terms(nouns)recognized by the morphological analysis engine MeCab and created a documentterm matrix. A value of“tf・idf”was calculated in this matrix for term weighting to avoid the effect of term frequency. We reduced the dimensionality of the matrix using singular v alue decomposition,which removed unnecessary data,and weextracted feature vectors attributed to each medical package insert. The distance between feature vectors was calculatedusing cosine distance,and cluster analysis was performed based on the distance between the vectors.Results:Cluster analysis on our document-term matrix show ed that medical package inserts of drugs that have the sameefficacy or active ingredient were included in the same cl uster. Moreover, using term weighting and dimensionalityreduction,we could extract topics from medical package inserts.Conclusion:We obtained a foothold to apply our findings t o the recommendation of similar drugs. Cluster analysis ofmedical package inserts using NLP can contribute to the pro per application of drugs. In addition,our study revealed thesimilarities of drugs and suggested possibilities for new applications from several points of view.
ABSTRACT
<b>Objective: </b>Pharmacists need to know at what positioning a drug is recommended in clinical practice guidelines when they make prescription proposals. However, the format of guidelines and the definition of recommendation grades differ between academic societies, making it difficult to comprehensively extract only the information one needs. Therefore, we developed a guideline utilization system to support prescription proposals by pharmacists.<br><b>Methods: </b>We built a database comprised of clinical practice guidelines on pharmacological therapy for breast cancer and breast cancer-related conditions. FileMaker®was used in the development of the system.<br><b>Result: </b>This system allows the comprehensive extraction of clinical questions and recommendations from multiple guidelines by means of standardized keywords.<br><b>Conclusion: </b>This system supports prescription proposals by pharmacists when generating pharmacological therapy protocols or when in discussions with healthcare professionals as information on the positioning of therapeutic agents in different guidelines and recommended drugs is readily available.
ABSTRACT
<b>Objective: </b>Distigmine can cause cholinergic crisis as the side effect. In 2010, the safety information of distigmine was announced and its dosage was changed up to 5 mg per day. However, the malpractice that a pharmacist dispensed over dose of distigmine caused severe health damages in a community pharmacy. Therefore, we made the protocol with the urologists for the appropriate use of distigmine, including contents of monitoring the side effects. The purpose of this study was to measure using the protocol was useful for the propulsion of proper use of distigmine.<br><b>Methods: </b>The protocol was introduced in 10 community pharmacies and 1 hospital pharmacy from December 2013 to April 2014, and the patients and pharmacists were filled out the answer to the questions that we have made. The protocol consisted of five main checks; the dosage, lower urinary tract symptom, presence of renal disease, combined drugs, and signs of the side effects. Each patient was filled out the checklist given by the pharmacist to monitor the signs of the side effects for 2 weeks.<br><b>Results: </b>The 3 prescriptions of distigmine (18.8%) were more than 10 mg per day. Although 2 patients were confirmed diarrhea and sweating etc., they were mild. The pharmacists significantly more (<I>p</I><0.05) answered that the protocol made their motivation to do the pharmaceutical interventions. All of the patients answered that the pharmaceutical interventions made them relieved.<br><b>Conclusion: </b>The use of protocol that we made supported pharmacists to do the pharmaceutical interventions and patients welcome them.
ABSTRACT
<b>Objective: </b>Tamoxifen is a drug that is frequently administered for 5 years to treat hormone receptor-positive breast cancer in premenopausal women. Metabolism of tamoxifen by cytochrome P450 enzymes such as CYP3A4 and CYP2D6 is required for drug efficacy. However, reports suggest that the effect of tamoxifen is attenuated in the presence of CYP2D6 inhibitors. In this study, I evaluated drug-drug interactions that may attenuate tamoxifen action for improved pharmaceutical management.<br><b>Data Source: </b>Potential interactions were evaluated by using the tamoxifen package insert, Kyoto Encyclopedia of Genes and Genomes (KEGG), Pharmaceuticals and Medical Devices Agency (PubMed), and Lexicomp Online. We have searched the paper using the PubMed and JDream III.<br><b>The Choice of Research: </b>The paper about the interaction related CYP2D6 and 3A4 of tamoxifen.<br><b>Results and Conclusion: </b>The use of tamoxifen is often long term; however, adverse effects such as hot flashes, can cause poor regimen adherence. Although selective serotonin reuptake inhibitors (SSRIs) can effectively treat menopausal hot flashes, many SSRIs inhibit CYP2D6. In particular, paroxetine has been reported to adversely affect tamoxifen metabolism. There are 31 drugs and 843 compounds that inhibit CYP2D6. Thus, it is necessary to avoid these combinations. In addition, there are many CYP2D6 gene polymorphisms that have been identified in Japanese patients, and some reports indicate that they affect tamoxifen efficacy. Therefore, in order to continue use of these medications without attenuating the effect of tamoxifen, development of medical database which can be updated daily is required to avoid CYP-related interactions.
ABSTRACT
<b>Objective: </b>To examine the usefulness of inquiries made by hospital pharmacists.<br><b>Methods: </b>This study was conducted a survey about the actual condition of inquiries at 5 hospitals.<br><b>Results: </b>The prescriptions subjected to inquiry accounted for 1.5% of the inpatient prescriptions and 0.3% of the injection prescriptions. In cases of “Incomplete entry in the prescription” for the subcategory of “Question about safety,” drug costs without the impact of pharmaceutical inquiries were calculated on the assumption that the concerned drugs should have been generally prescribed. Our results showed that the total savings in medical costs were 30,673 yen for the inpatient prescriptions and 159,212 yen for injection prescriptions, which suggested that pharmaceutical inquiries are effective for saving medical costs for either type of prescriptions. In the case of patients in whom adverse drug reactions (ADRs) might have occurred without prescription changes, medical cost savings realized by preventing ADRs were estimated using the Diagnosis Procedure Combination/Per-Diem Payment System (DPC/PDPS). Our results showed that the savings were 1,428,710 yen for inpatient prescriptions (6 patients), which indicated that a large amount of medical costs was saved.<br><b>Conclusions: </b>Our results suggested that similar to pharmaceutical inquiries made by community pharmacists, those made by hospital pharmacists not only result in the proper delivery of drug therapy but also are useful in terms of medical economics.
ABSTRACT
<b>Objective: </b>Pharmacotherapy for patients with breast cancer is now administered in an ambulatory setting, and we assume that patients would benefit if clinical pharmacists perform all stages of pharmacological intervention up to prescription in an ambulatory setting as well, especially for medicines requiring chronic administration and those that affect the patient’s life, such as hormonal therapy. A thorough understanding of guidelines and the clinical reports is paramount for effective pharmacological intervention. Since ambulatory care clinical pharmacists are involved in the treatment of a large number of patients, effective utilization of evidence outlined in guidelines and clinical reports is difficult. Therefore, we developed a system for utilizing evidence as outlined in guidelines and clinical reports with a focus on hormonal therapy for patients with breast cancer.<br><b>Methods: </b>A database based on the 2013 version of the clinical practice guidelines for breast cancer and clinical reports was constructed using Microsoft® Access 2010.<br><b>Result: </b>Clicking on a guideline algorithm according to the disease stage of the patient results in a clinical question being displayed, and the ambulatory care clinical pharmacist is immediately able to determine suitable medications based on clinical reports that are run through the database.<br><b>Conclusion: </b>With the use of this database, which includes information required for pharmacological intervention, ambulatory care clinical pharmacists could care for a large number of patients.